XL092 and Cemiplimab in BRAF WT Thyroid Cancer
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Recruiting · NCT06902376 · Registry updated 2026-10-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| XL092 and Cemiplimab in BRAF WT Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, thyroid gland disorder, thyroid gland undifferentiated (anaplastic) carcinoma, thyroid tumor | Recruiting | Phase 1 | 2026-10-05 | NCT06902376 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Exelixis | 77 |
| Regeneron Pharmaceuticals | 238 |
| UNC Lineberger Comprehensive Cancer Center | 125 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber/Harvard Cancer Center | Boston | United States | 4 |
| University of North Carolina at Chapel Hill | Chapel Hill | United States | 129 |